Target intelligence / Profile preview

Cell division cycle protein 23 homolog (CDC23)

Target
CDC23
Molecular classification
Enzyme, Ubiquitin ligase subunit, Anaphase-promoting complex subunit, Tetratricopeptide repeat domain-containing protein
01

Overview

Cell division cycle protein 23 homolog (CDC23) is an essential subunit of the anaphase-promoting complex/cyclosome (APC/C), a large, multisubunit E3 ubiquitin ligase that controls progression through mitosis and G1 phase by catalyzing ubiquitin-mediated degradation of key regulators such as cyclin B1 and securin[2][3][4]. It contains tetratricopeptide repeat (TPR) domains important for protein–protein interactions within the complex. CDC23 is critical for orderly cell cycle transition, and its dysfunction causes cell cycle arrest, inhibits proliferation, and is linked to several cancers[1][3][4]. Recent studies indicate CDC23 may contribute to tumorigenesis and metastasis by regulating the epithelial-mesenchymal transition (EMT), and its expression is significantly higher in various cancer cell types, making it a potential novel therapeutic target[1][3][4].

Other names
Anaphase-promoting complex subunit 8APC8ANAPC8CUT23Cyclosome subunit 8
02

Mechanism of action

Inhibition or knockdown causes arrest in G2/M phase by blocking ubiquitin-mediated degradation of key cell cycle regulators (e.g., cyclin B1, securin)

03

Biological functions

Cell cycle progressionRegulation of mitosis (G2/M transition)Ubiquitin-mediated protein degradationMaintenance of genomic stabilityRegulation of epithelial-mesenchymal transition (EMT)
04

Disease associations

Cancer (including liver cancer and papillary thyroid cancer)Potential role in cell proliferation disorders
05

Safety considerations

Targeting CDC23 may affect normal cell cycle progression, leading to possible toxicity due to impaired mitosis in normal proliferating cellsPotential for genomic instability with improper modulation
06

Biomarkers

Overexpression in certain cancers (e.g., liver and thyroid cancers) indicates proliferation and metastatic potentialChanges in EMT markers (E-cadherin up, N-cadherin and vimentin down) after CDC23 knockdown

Beyond the preview

Go deeper on Cell division cycle protein 23 homolog (CDC23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell division cycle protein 23 homolog (CDC23).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call